Table 2. Summary of results of trails concerning PD-1 inhibitors.
| Study | Drugs | Subgroup | No. | ORR (%) | mPFS (month) | mOS (month) |
| PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; ORR, objective response rate; mPFS, median progression-free survival; mOS, median overall survival; TNBC, triple-negative breast cancer; CPS, combined positive score; NA, not available. | ||||||
| KEYNOTE-
012 (24) |
Pembrolizumab | TNBC | 27 | NA | 1.9 | 11.2 |
| KEYNOTE-
086(A) (25) |
Pembrolizumab | mTNBC | 170 | 5.3 | 2.0 | 9.0 |
| PD-L1+ (CPS≥1) | 105 | 5.7 | 2.0 | 8.8 | ||
| PD-L1− (CPS<1) | 64 | 4.7 | 1.9 | 9.7 | ||
| KEYNOTE-
086(B) (27) |
Pembrolizumab | TNBC | 84 | 21.4 | 2.1 | 18.0 |
| KEYNOTE-
119 (26) |
Pembrolizumab/
single-agent chemotherapy |
TNBC (Pemb) vs. TNBC (chemo) | 312 vs. 310 | 9.6 vs. 10.6 | 2.1 vs. 3.3 | 9.9 vs. 10.8 |
| PD-L1+ (CPS≥1) (Pemb vs. chemo) | 203vs. 202 | 12.0 vs. 9.0 | 2.1 vs. 3.1 | 10.7 vs. 10.2 | ||
| PD-L1+ (CPS≥10) (Pemb vs. chemo) | 96 vs. 98 | 18.0 vs. 9.0 | 2.1 vs. 3.4 | 12.7 vs. 11.6 | ||
| PD-L1+ (CPS≥20) (Pemb vs. chemo) | 57 vs. 52 | 26.0 vs. 12.0 | 3.4 vs. 2.4 | 14.9 vs. 12.5 | ||
| KEYNOTE-
355 (40) |
Chemotherapy +
pembrolizumab/ placebo |
ITT | 566vs. 281 | 40.8 vs. 37.0 | 7.5 vs. 5.6 | 17.2 vs.15.5 |
| PD-L1+ (CPS≥1) | 425 vs. 211 | 44.9 vs. 38.9 | 7.6 vs. 5.6 | 17.6 vs. 16.0 | ||
| PD-L1+ (CPS≥10) | 220 vs, 103 | 52.7 vs. 40.8 | 9.7 vs. 6.5 | 23.0 vs. 16.1 | ||
| TONIC (41) | Nivolumab+ 1) without induction or with 2-week low-dose induction/2) irradiation (3 × 8 Gy)/3) cyclophosphamide/4) cisplatin/5) doxorubicin | Overall cohort | 66 | 20 | 1.9 | NA |
| Without induction or with 2-week low-dose induction | 12 | 17 | NA | NA | ||
| Irradiation | 12 | 8.0 | NA | NA | ||
| Cyclophosphamide | 12 | 8.0 | NA | NA | ||
| Cisplatin | 13 | 23.0 | NA | NA | ||
| Doxorubicin | 17 | 35.0 | NA | NA | ||
| KEYNOTE-
162 (44) |
Niraparib +
pembrolizumab |
Full analysis | 47 | 21.0 | 2.3 | NA |
| tBRCAmut | 15 | 47.0 | 8.3 | NA | ||
| tBRCAwt | 27 | 11.0 | 2.1 | NA | ||
| tBRCAunknow | 5 | 0 | 2.5 | NA | ||
| PD-L1 unknown | 6 | 0 | NA | NA | ||
|
NCT03394287
(20) |
Apatinib +
camrelizumab |
All population | 40 | 32.5 | NA | NA |
| Intermittent dosing | 10 | 0 | 1.9 | 9.5 | ||
| Continuous dosing | 30 | 43.3 | 3.7 | 8.1 | ||